Plasmodium falciparum is the causative agent of human falciparum malaria and is responsible for a huge burden of global mortality and morbidity (Ref. 1) . The parasite has a complex life cycle involving both human and mosquito hosts ( Fig. 1) , and despite more than a century of research, has proven recalcitrant to control and eradication measures. The clinical features of malaria occur during the blood stage of infection, when the parasite grows and When an infected female Anopheles mosquito takes a blood meal, sporozoite forms of P. falciparum are injected into the human skin. The sporozoites migrate into the bloodstream and then invade liver cells. The parasite grows and divides within liver cells for 8-10 days, then daughter cells called merozoites are released from the liver into the bloodstream, where they rapidly invade erythrocytes. Merozoites subsequently develop into ring-stage, pigmented-trophozoite-stage and schizontstage parasites within the infected erythrocyte. P. falciparum-infected erythrocytes express parasite-derived adhesion molecules on their surface, resulting in sequestration of pigmented-trophozoite and schizont stages in the microvasculature. The asexual intraerythrocytic cycle lasts for 48 hours, and is completed by the formation and release of new merozoites that will re-invade uninfected erythrocytes. It is during this asexual bloodstream cycle that the clinical symptoms of malaria (fever, chills, impaired consciousness, etc.) occur. During the asexual cycle, some of the parasite cells develop into male and female sexual stages called gametocytes that are taken up by feeding female mosquitoes. The gametocytes are fertilised and undergo further development in the mosquito, resulting in the presence of sporozoites in the mosquito salivary glands, ready to infect another human host.
Life cycle of Plasmodium falciparum
multiplies within the human host erythrocytes (Fig. 1) . The presence of the parasite and the resulting host inflammatory responses lead to high fevers and associated 'flu'-like symptoms. In 1 -2% of infections a life-threatening illness develops, characterised by various clinical features, including impaired consciousness, coma, difficulty breathing, severe anaemia and multi-organ failure (Refs 2, 3). These clinical manifestations of severe malaria are thought to occur because of a combination of a high parasite burden and the sequestration of mature P. falciparum-infected erythrocytes (IEs) in microvascular beds throughout the body (Ref. 4) . The sequestered mass of IEs leads to microvascular obstruction (Refs 5, 6), metabolic disturbances, such as acidosis (Ref. 7) , and release of damaging inflammatory mediators (Refs 8, 9), which can combine to cause severe disease and death of the human host. Sequestration is thought to benefit the parasite by allowing it to avoid the host's normal splenic clearance mechanisms that remove aged or damaged erythrocytes (Ref. 10 ).
The importance of Plasmodium falciparum adhesion Three major types of Plasmodium falciparum adhesion Sequestration occurs because parasite-derived adhesins expressed on the surface of mature-IEs bind to receptors on human cells. Three major types of IE adhesion have been described ( (3) interactions with platelets that can lead to clumping of IEs in vitro (platelet-mediated clumping) (Ref. 13 ).
An additional specialised form of adhesion occurs during malaria in pregnancy, in which IEs adhere to syncytiotrophoblasts to bring about placental sequestration (Ref. 14) . The molecular mechanisms of placental sequestration and the drive to develop a vaccine to prevent malaria in pregnancy are covered elsewhere (Refs 15, 16, 17) and are not discussed here. IEs are also known to bind to a variety of immune system cells, which has important immunological consequences. These immunological interactions are considered briefly below; however, the review focuses mainly on the first three major types of adhesion, and considers progress in elucidating the molecular mechanisms of adhesion and the therapeutic implications of understanding these important host-parasite interactions.
Which adhesion phenotypes are important in the pathogenesis of severe malaria?
An important prerequisite for the development of new treatments is an understanding of how different types of adhesion contribute to malaria pathogenesis. All P. falciparum isolates sequester, yet not all infections lead to lifethreatening disease. So, are all types of parasite adhesion equally damaging? Or is lifethreatening malaria linked to specific binding phenotypes that can target IEs to vital organs such as the brain, or cause particularly severe microvascular obstruction? There are, as yet, no definitive answers to these crucial questions. However, current data suggest that there might be geographic variation in the association between adhesion phenotypes and severe disease (discussed further below).
Discovering which parasite adhesion phenotypes contribute to life-threatening malaria has proved difficult because there is no animal model that reflects the pathogenesis of human malaria. Researchers have therefore used two approaches to investigate parasite adhesion phenotypes in relation to disease severity. The first compares the binding properties of field isolates derived from blood samples of patients with different clinical forms of malaria. Binding of IEs is assessed in static or flow assays using purified host receptors bound to plastic dishes, cell lines, fluorescently labelled receptors or receptor-coated beads. The aim of these studies is to identify parasite adhesion phenotypes that occur at high frequency (or show high levels of binding) in isolates from patients with severe malaria, but are rare (or show low levels of binding) in isolates from patients with uncomplicated disease. A positive correlation between a parasite adhesion phenotype and severe disease supports a role for that phenotype in pathogenesis. A negative result does not, however, prove the phenotype is unimportant, because the assays might not adequately reflect adhesion in vivo. A second approach has been to use human genetic studies to investigate whether receptor polymorphisms that reduce parasite adhesion confer protection against severe malaria. The rationale for these studies is that if an adhesion phenotype is directly involved in causing life-threatening malaria, then any human receptor polymorphism that reduces or abolishes parasite adhesion should confer protection against severe disease and death. Examples of both types of study are given below.
Geographic variation in pathogenic mechanisms linked to malaria transmission intensity and host immunity
There are distinct patterns of severe malaria in different parts of the world linked to differences in malaria transmission intensity. For example, in South East Asia, where transmission is generally low, severe malaria affects all age Adhesion of erythrocytes infected with Plasmodium falciparum to human cells groups and commonly presents as multiorgan failure (including renal and hepatic failure, pulmonary oedema and impaired consciousness) (Ref. 18 ). Individuals suffering from severe malaria in SE Asia usually have had few, if any, previous malaria infections. Conversely, in sub-Saharan Africa, transmission levels tend to be higher and more stable, and severe malaria is mainly a disease of children under 5 years that presents as impaired consciousness, severe anaemia or respiratory distress (Ref. 2). In sub-Saharan Africa, patients suffering from severe malaria are likely to have had multiple previous P. falciparum infections (Ref. 19) . The distinct clinical features of severe malaria in different parts of the world are probably age-related, because a recent study from a low-transmission area in Asia shows that age has a large effect on presenting syndromes, with seizures, respiratory distress and anaemia being more common in children, whereas renal and hepatic failure are more commonly seen in adults (Ref. 3) .
It remains unclear to what extent the different levels of host immunity to malaria that occur under different transmission intensities influences host-parasite interactions. The possibility that parasite phenotypes contributing to severe disease might differ in distinct geographical regions related to transmission intensity has received little attention, but is supported by recent research. In SE Asia, a high parasite multiplication rate in vitro and the ability of parasites to invade erythrocytes nonselectively are linked to severe disease (Refs 20, 21), whereas these factors are not associated with disease severity in Africa (Ref. 22 ). There is a direct link between total parasite burden and risk of severe malaria and death in SE Asia (Refs 23, 24), whereas the relationship is less clear in sub-Saharan Africa, where some children tolerate extremely high parasitaemia without developing severe clinical complications (Refs 2, 25). In terms of adhesion phenotypes, rosetting is associated with severe malaria in African children (Refs 13, 22, 26, 27, 28, 29, 30, 31, 32, 33), but is not associated with malaria severity in SE Asia (Refs 34, 35, 36, 37). The possible reasons why different parasite properties are linked to severe malaria in different regions are discussed further below. In addition, because of the potential geographic variation in parasite adhesion phenotypes underlying severe malaria, we discuss studies from areas with unstable or low transmission (usually SE Asia) separately to studies from areas with stable or moderate -high transmission (sub-Saharan Africa or Papua New Guinea).
Molecular mechanisms of P. falciparum adhesion
In 1995, the cloning of the var genes encoding the variant surface antigen family P. falciparum erythrocyte membrane protein 1 (PfEMP1) provided essential groundwork for research into the molecular basis of adhesion in falciparum malaria (Refs 38, 39, 40) . PfEMP1 variants are expressed on the surface of IEs and are responsible for at least some of the adhesive 
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Host receptors Figure 3 . Schematic representation of a parasite-derived Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variant on the surface of an infected erythrocyte. PfEMP1 is a family of proteins encoded by var genes that are transported and expressed on the surface of infected erythrocytes during the mature stages of the intraerythrocytic cycle (pigmented trophozoite and schizont). There are approximately 60 var genes per parasite genome, which encode 60 different variants of PfEMP1; however, only one particular variant of PfEMP1 is expressed per cell at any given time. Switching of var gene expression allows the parasite to modify the antigenic and functional properties of infected erythrocytes, thereby evading immunity and altering adhesion capabilities. The extracellular region of PfEMP1 has an N-terminal segment (NTS) followed by several cysteine-rich domains known as DBL (duffy-binding-like) and CIDR (cystein-rich interdomain regions) that can be classified into distinct types based upon sequence similarity. There are six DBL types, (a, b, g, d, 1 and X) and three CIDR types (a, b and g). The number, location and type of DBL and CIDR domains vary among PfEMP1 variants, and this variable domain composition and extensive sequence polymorphism is thought to provide great flexibility in binding properties. For each P. falciparum adhesion phenotype, a summary is given below describing what is known about the molecular basis of adhesion, including information on the host receptor, the parasite ligand and the role of the adhesion phenotype in the pathogenesis of severe malaria.
Molecular mechanisms of infected erythrocyte adherence to endothelial cells
The ability of IEs to bind to microvascular endothelial cells and become sequestered from the peripheral blood was described in postmortem studies of patients who died from falciparum malaria in the 1890s (Ref. 51) . Since then, cytoadherence has received considerable attention, and although much has been learned, many major questions remain unanswered. P. falciparum IEs have been shown to have the potential for binding to a diverse array of endothelial receptors (Table 1) . Evidence for many of these interactions is based on a single, or small number of publications, and only CD36 and intracellular adhesion molecule 1 (ICAM1) have been studied in detail. The neglect of this important area is surprising, as is the fact that it remains unclear which, if any, of these receptors has a pivotal role in the most life-threatening forms of malaria. Each receptor is considered individually below; however, it is important to remember that in vivo, multiple receptors might combine to promote adhesion to endothelial cells (Refs 52, 53 
Molecular mechanisms of IE rosetting
The ability of IEs to bind uninfected erythrocytes to form rosettes (Fig. 2C) (Refs 12, 114 ) varies between isolates, and high levels of rosetting are significantly associated with severe malaria at several sites across sub-Saharan Africa (Table 1) . However, such an association between rosetting and severe disease is not seen in SE Asia (Table 1) Molecular mechanisms of P. falciparum adhesion to platelets P. falciparum IEs have the capacity to bind platelets and form mixed clumps in vitro, in which platelets act as bridges between the IEs (platelet-mediated clumping, Fig 2D) There is currently very little evidence to determine whether P-selectin binding is important in severe malaria (Table 1) .
Molecular mechanisms of IE interaction with cells of the immune system
Many of the receptors involved in adhesion of P. falciparum to endothelial cells, erythrocytes and platelets are also present on subsets of leukocytes, including CD36, ICAM1, NCAM (CD56), gC1qR, CR1 and the A and B blood group antigens. Therefore the potential exists for parasites to bind to leukocytes and promote immune cell activation and parasite clearance, or lead to immunomodulation and immune evasion. A consensus on whether these interactions are beneficial or detrimental to the human host is still lacking. Of these immune cell receptors, CD36 is the most well studied, yet it remains the most controversial. Binding of IEs to macrophage CD36 leads to phagocytosis without the production of pro-inflammatory cytokines (Ref. 144) , suggesting that CD36 binding could lead to parasite clearance and so favour the host. Other evidence shows that parasite adhesion to CD36 is implicated in the impairment of human dendritic cell function and subsequent inhibition of the adaptive immune response (Refs 145, 146) , and so could favour the parasite. However, recent evidence suggests that parasite adhesion to CD36 (or any other receptor) is not required for the modulation of dendritic cell function, and instead a high dose of parasitised red blood cells is sufficient to induce inhibition of dendritic cell maturation (Ref. 147) .
Adhesion of malaria parasites to cells of the lymphocyte lineage has also been reported. Adhesion of malaria parasites to leukocytes is complex. Many known P. falciparum receptors with a potential immunomodulatory function have yet to be investigated and even for those receptors that have been studied in detail, the physiological significance of the interaction is largely unresolved. The potential dual role of CD36, both in phagocytic clearance of parasites and in immunosuppression of dendritic cells, serves as a warning that the therapeutic disruption of P. falciparum adhesion could have unintended immunological consequences. On the basis of current knowledge, any therapeutic intervention able to reverse adhesion of IEs has the potential to relieve microvascular obstruction and could be tested as an adjunct to standard antimalarial drugs in severely ill malaria patients. New treatments are urgently needed because the case mortality rate for severe malaria is [15] [16] [17] [18] [19] [20] , even in wellequipped hospitals with intensive care facilities (Ref. 159) . Standard antimalarial drugs take up to 24 hours for their parasite-killing effects to occur, and 85% of malaria-related deaths in hospitalised patients occur in the 24 hour period immediately after hospital admission (Ref.
Clinical implications and possible therapeutic applications Potential for antiadhesion therapies

2).
The superior results obtained with artemisinine derivatives over quinine as a first-line antimalarial treatment in SE Asian adults with severe malaria (Ref. 160 ) might be due to the faster action of artemisinine, which acts on all stages of parasite development, whereas quinine only kills schizonts and mature trophozoites (Ref. 161) . Even in artemisinine-treated patients, it is plausible that a therapy that immediately relieves microvascular obstruction might be of clinical benefit. It is less clear whether therapies that are able to block further adhesion but are unable to reverse existing adhesion would be useful, and it seems prudent to suggest that development of adhesion-reversing agents should be given priority.
Adhesion-reversing therapies are likely to be drugs, and ideally should be easy and cheap to manufacture, have minimal side effects and good stability (Ref. 162) . Drugs that are already in clinical use for other diseases have an advantage in terms of development time and costs, and some of the current candidate antiadhesion therapies fall into this category. Infusions of monoclonal antibodies or peptides might also have the potential to reverse adhesion, although it seems unlikely that such interventions would be cheap enough to be widely used in developing countries with limited resources for health care. Monoclonal antibody or peptide therapies could, however, provide proof of principal to determine whether adhesion-reversal is of clinical benefit, and might be used in intensive care facilities in more affluent countries.
Potential for antiadhesion vaccines
Knowledge of the molecular mechanisms of parasite adhesion could be used to design vaccines aimed at raising antibodies to block adhesion and prevent sequestration. The spleen would remove nonsequestered mature IEs, and so the build-up of high parasite burdens of avidly sequestering parasites would be avoided and severe malaria prevented. The vaccine approach is problematic because of the variability of the parasite adhesion ligand PfEMP1, although initial exploratory studies are underway (Refs 163, 164, 165) , and some preliminary data do support the possibility that crossreactive antibodies can be active against a range of isolates (Refs 166, 167). Another problem would be the logistical difficulty and cost of testing such a vaccine, for which reduced malaria mortality would be the primary endpoint.
Although challenging, the development of an adhesion-blocking vaccine would be of great value because it would have the potential to reduce deaths from malaria amongst the many people who currently do not have access to treatment in well-equipped hospitals. For this reason, even if adhesionreversing adjunctive therapies to be used in hospitals can be developed, research into adhesion-blocking vaccines should also proceed, although the possibility that blood-stage vaccines expert reviews could drive the evolution of parasite virulence should be considered (Ref. 168 ).
Current antiadhesion drugs under investigation
Drugs that are currently under investigation for their potential as antiadhesion adjunctive therapies are summarised in Table 2 .
Drugs to inhibit or reverse CD36 binding Levamisole
Levamisole is an alkaline phosphatase inhibitor that is used as an antihelminth drug in humans. Recent research showed that endothelial CD36 is constitutively phosphorylated and that interaction with IEs leads to phosphatase activity to remove the phosphate group at Thr92 of CD36 (Refs 169, 170).
Dephosphorylated CD36 has a higher affinity for IEs under flow conditions than phosphorylated CD36 does, and inhibition of phosphatase activity using levamisole leads to a twofold reduction in IE binding in vitro (Ref. 170) . A randomised clinical trial of Thai patients with uncomplicated malaria (12 treated with levamisole and 9 controls) showed that levamisole, used as an adjunctive therapy with quinine and doxycycline, resulted in increased numbers of early -mid trophozoites in the peripheral blood (Ref. 171) . It was suggested that levamisole prevented the sequestration of these parasites as they matured from ring stages following treatment. There was no evidence for a reversal of adhesion of existing mature sequestered forms, and schizonts were not seen in the peripheral blood (although it is Despite these encouraging preliminary results, a large randomised clinical trial of NAC as an adjunctive treatment for severe malaria, using mortality as an endpoint, has not been reported. Indeed, a recent study showed that NAC can interfere with the action of artesunate during the first 6 hours of coincubation with P. falciparum in vitro, and cautioned against the use of NAC as an adjunctive treatment with artemisinine derivatives (Ref. 177) . The interaction between the two drugs is thought to occur because the parasitocidal effect of artemisinine takes place via oxidative damage, which may be inhibited by the antioxidant effect of NAC. The possibility of antagonism between NAC and the most effective current antimalarial drug might mean that further tests of NAC as an adjunctive therapy will be hard to justify.
Recombinant PfEMP1 peptide
A peptide corresponding to the minimal CD36-binding region of PfEMP1 from the Malayan Camp parasite strain (Refs 65, 178) has been shown to inhibit adhesion of Thai field isolates to an endothelial cell line in vitro under flow conditions, and to reverse adhesion to microvessels in vivo in a human skin graft in SCID mice (Ref. 179) . This peptide might have potential as an adhesion-reversing therapy, although it is unclear if it would be practical for widescale use.
Drugs to inhibit ICAM1 binding (1)Epigalloyl-catechin-gallate
The best example to date of the rational design of a compound to block cytoadherence comes from Dormeyer and co-workers (Ref. 180) , who used the crystal structure of ICAM1 to identify a compound to block parasite binding to ICAM1 in vitro. The team used in silico screening to identify compounds that mimicked the region of ICAM1 that is involved in IE binding (Ref. 76) . Thirty-six candidates were identified in an initial screen, and these were then tested in vitro for the ability to inhibit IE adhesion to ICAM1 under flow conditions. One compound, (þ)epigalloyl-catechin-gallate [(þ)EGCG], was identified that inhibited binding by 50% at micromolar concentrations (Ref. 180). However, this compound did not reverse adhesion. EGCG is a naturally occurring polyphenol compound that is a constituent of green tea and is currently being investigated for its anticancer, anti-inflammatory and anti-infective properties (Refs 181, 182, 183) . Substantial further work will be required to translate these promising preliminary findings into a useable adjunctive therapy, and one major question that will need to be addressed is whether the evidence for an involvement of ICAM1 binding in severe malaria is currently strong enough to justify the resources required for drug development. Whether this compound proceeds towards the clinic or not, the study by Dormeyer and colleagues (Ref. 180) remains an excellent illustration of how detailed structural and molecular information can be used for rational drug design in malaria.
Drugs to improve endothelial cell function L-arginine L-arginine is the substrate for the synthesis of NO by NO synthase. It is given intravenously and has been used safely in humans for many years, both in endocrine system investigations and as a potential therapeutic agent in cardiovascular diseases. Following on from studies in patients showing low NO production and low plasma arginine levels in severe malaria (Refs 184, 185) 
Drugs to reverse rosetting Sulphated glycoconjugate compounds
A variety of sulphated glycoconjugate compounds are known to reverse P. falciparum rosetting ( Refs 190, 191, 192) ; however, many of these compounds also have significant anticoagulant properties that could cause sideeffects. A heparin derivative with reduced anticoagulant effects has some therapeutic potential (Ref. 193) , but the rosette-disrupting effect of heparin and its derivatives is strainspecific (effective on about 30-50% of rosetting isolates) (Ref. 190) , which may limit its usefulness.
Another sulfated glycoconjugate that had broader rosette-disrupting activity against a wide range of parasite isolates is curdlan sulphate (Ref. 194 ) -a drug initially developed as an AIDS therapy (Ref. 195) . Curdlan sulphate has been shown to be safe in adult patients with malaria in SE Asia (Ref. 196) . However, this is not the most appropriate target population for testing the anti-rosetting effects of the drug and it needs be tested as an adjunctive therapy for severe malaria in African children.
Soluble CR1
Recombinant soluble CR1 (sCR1) is being developed as a drug in humans for ischaemiareperfusion injuries (such as infarcts and strokes) (Refs 197, 198) or immune-mediated haemolysis and transfusion reactions (Ref. 199) . sCR1 disrupts rosettes in some but not all P. falciparum rosetting isolates (Ref. 117); therefore, it is possible that sCR1 could be of benefit as an adjunctive therapy for severe malaria. However, further information is required on the ability of sCR1 to disrupt rosettes in a broad range of clinical isolates.
Drugs to inhibit or reverse platelet binding
Owing to the involvement of platelets in important pathological conditions such as thrombosis and atherosclerotic vascular diseases, there are numerous antiplatelet therapies available for human use [e.g. acetylsalicylic acid (aspirin), dipyridamole, cilostazol, ticlopidin, clopidogrel, abciximab (ReoPro), eptifibatide and tirofiban] ( Refs 200, 201) . The mechanisms of action of these drugs are well understood; however, because so little is known about the mechanisms and consequences of interactions between P. falciparum and platelets, it is difficult to predict whether any of these compounds might be beneficial in severe malaria. A recent report suggests that some antiplatelet drugs, such as aspirin, could actually be detrimental in malaria, by preventing the parasite-killing effects of platelets (Ref. 140) . Further research is needed to clarify the role of platelets in malaria pathophysiology to take advantage of the therapeutic options in this area.
Prospects and outstanding research questions Assessing which adhesion phenotypes contribute to severe malaria Currently, our incomplete understanding of the adhesion mechanisms important in the most life-threatening clinical forms of malaria is a major obstacle to the development of adjunctive therapies. Given the huge amount of time, effort and money required for drug development, only those adhesion interactions whose involvement in severe malaria is backed by strong scientific evidence are likely to succeed in raising funding for drug development and clinical trials. The logistic and technical difficulties of carrying out field-isolate adhesion studies might be one reason for the neglect of this important area. For future expert reviews http://www.expertreviews.org/ in molecular medicine studies, flow-based systems examining IE binding to endothelial cell lines probably provide the most physiologically relevant approach, and allow investigation of rolling as well as static adhesion, and synergism between receptors that might be important in vivo (Ref. 52).
Another difficulty is the varying definition of severe malaria used in many studies and the choice of a suitable control group for comparison with severe malaria patients (Ref. 202) . 'Severe malaria' is often considered to be a single disease entity, whereas it is possible that different adhesion phenotypes contribute to distinct clinical syndromes, such as cerebral malaria (unrousable coma), respiratory distress (difficulty breathing) and severe malarial anaemia (haemoglobin levels ,5 g/dl). Ideally, studies of parasite adhesion in relation to malaria severity should use clearly defined subtypes of severe disease, although this could be difficult because of overlap in syndromes in many patients, and small numbers in some categories.
Another problem with studies of parasite adhesion phenotypes and severe malaria is the uncertainty as to whether the phenotype of the parasites being tested (derived as ring stages from peripheral blood and matured in vitro for 12-24 hours) truly reflects the phenotype of the sequestered mass of parasites that are not accessible for experimentation, although recent data suggest no substantial genetic differences between the two populations (Ref. 203 ).
Possibility of geographic variation in parasite adhesion phenotypes causing severe malaria As described above, there are clear differences in parasite phenotypes linked to severe disease in studies from low-transmission areas such as SE Asia (high multiplication rate and nonselective invasion) compared with moderate -high transmission areas such as sub-Saharan Africa (rosetting).
How might these regional differences be explained, and could differences in levels of host immunity be an important factor?
One consistent feature of severe malaria throughout the world is that mortality is linked to markers of metabolic acidosis, such as base excess (Ref. 3) In sub-Saharan Africa, however, where individuals are exposed to multiple P. falciparum infections, parasite growth in the human host might occur in the presence of immune responses that reduce parasite proliferation. In particular, initial infections in infants might be modified by in utero exposure to plasmodial antigens or by maternal antibody acquired through the placenta or via breast milk, and entirely immunologically naive individuals in relation to Plasmodium infection may be rare. In this case, it is possible that only parasite isolates expressing adhesion phenotypes that are most effective at promoting parasite growth and survival in the face of host immunity are able to expand rapidly enough to reach high parasite burdens and cause severe disease, before specific antibodies to variant surface antigens develop. Rosetting, for example, is associated with high parasitaemia in vivo (Refs 205, 206) , and might act either by promoting red cell invasion (not supported by recent evidence) (Refs 207, 208) or as an immune-evasion mechanism that reduces parasite clearance (R.A.C. and J.A.R., unpublished results). Other adhesion phenotypes might exist that enhance parasite survival in partially immune hosts. In this scenario, specific adhesion phenotypes, such as rosetting, do contribute to severe malaria.
Implications of geographic variation for antiadhesion therapies
The above argument is speculative; however, it does fit with existing data. If such regional differences do exist (linked to malaria transmission intensity and host immunity) this has major therapeutic implications. For example, a rosette-disrupting drug might be of clinical benefit in sub-Saharan Africa but would expert reviews http://www.expertreviews.org/ in molecular medicine not be an appropriate treatment for severe malaria in SE Asia. Conversely, a drug that reverses CD36 binding might be more effective in SE Asia. Geographical variation needs to be considered carefully and merits further investigation to ensure that potentially life-saving drugs are tested on the most appropriate patient population. Furthermore, it should not be assumed that an antiadhesion therapy that works in a nonimmune population will be effective in a moderate -high transmission area, and vice versa.
Possible problems with antiadhesion therapies
One unanswered question in the approach of reversing adhesion is whether the release of large numbers of mature IEs into the circulation could be damaging. Would the spleen be able to cope with removing millions of IEs, or could it lead to potentially catastrophic side effects such as splenic rupture? In a saimiri monkey model of falciparum malaria, immune serum was used to reverse sequestration, without any damaging effect to the animals, supporting the safety of this approach (Ref. 209 ).
Another problem is the lack of an animal model that truly reflects the pathophysiology of severe falciparum malaria in humans, because it is not currently possible to test antiadhesion therapies in a meaningful way (none of the primate or rodent models develop clinical and pathological features similar to those in humans). Attempts have been made to develop animal models of sequestration (Refs 210, 211); however, their relevance to human disease mechanisms is unclear and unproven. Human vasculature grafted onto immunodeficient mice has been used successfully to investigate sequestration and antiadhesion drugs (Refs 55, 179). Further research in this area would clearly be of benefit, and the development of humanised animal models and transgenic parasites to enable study of specific human: P. falciparum receptorligand interactions might be one way forward (Ref. 212) .
A further potential problem with adhesionreversing therapies is the possibility that many severe malaria patients might be too far down the 'pathogenesis pathway' by the time they reach hospital to derive benefit from treatment. Reversing IE adhesion in moribund patients could amount to shutting the stable door after the horse has bolted. However, this cannot be predicted in advance and only carefully designed and adequately powered clinical trials will provide the answer to whether adhesionreversing therapies can save lives.
Conclusion
Despite the above problems, the pressing need for novel adjunctive therapies to lower the mortality rate from severe malaria argues strongly for further research in this area. Antiadhesion therapies have great potential for saving lives (Ref. 213 ) and further research to clarify the adhesion phenotypes causing severe malaria and development of interventions to reverse adhesion should be a priority for malaria research in the next decade. Figure 1 . Life cycle of Plasmodium falciparum. Figure 2 . Adhesion of Plasmodium falciparum-infected erythrocytes to human cells. Figure 3 . Schematic representation of a parasite-derived Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variant on the surface of an infected erythrocyte. Tables  Table 1. Summary of known receptors for P. falciparum adhesion. Table 2 . Current candidate drugs for antiadhesion adjunctive therapy of severe malaria.
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